This inventor holds 3 USPTO granted patents and 3 published patent applications and 1 EPO patent. Top assignee: Actelion Pharmaceuticals Ltd. Active years: 2022-2023.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Location History:
- Chapel Hill, NC (US) (2022)
- Raritan, NJ (US) (2022 - 2023)
Company Filing History:
Years Active: 2022-2023
Title: Innovations by Wassim Fares in Pharmaceutical Composition
Introduction
Wassim Fares is a notable inventor based in Chapel Hill, NC (US). He has made significant contributions to the field of pharmaceuticals, particularly in the treatment of pulmonary hypertension. With a total of 3 patents to his name, his work focuses on innovative compositions that aim to improve patient outcomes.
Latest Patents
Wassim Fares' latest patents include a pharmaceutical composition comprising macitentan for the treatment of chronic thromboembolic pulmonary hypertension (CTEPH). This invention relates to high doses of macitentan, which is used for the treatment and prevention of CTEPH. Additionally, he has developed a pharmaceutical composition for the treatment of pulmonary arterial hypertension (PAH), also utilizing high doses of macitentan. Both inventions emphasize the importance of dosage regimens and combinations with other therapeutic agents to enhance efficacy.
Career Highlights
Wassim Fares is currently associated with Actelion Pharmaceuticals Ltd, where he continues to innovate in the pharmaceutical sector. His work has been instrumental in advancing treatments for serious health conditions, showcasing his commitment to improving patient care.
Collaborations
Wassim has collaborated with notable coworkers such as Koen Torfs and Dénes Csonka, contributing to a dynamic team focused on pharmaceutical advancements.
Conclusion
Wassim Fares stands out as an influential inventor in the pharmaceutical industry, with a focus on innovative treatments for pulmonary hypertension. His contributions are paving the way for improved therapeutic options for patients.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile